olivLaw · US equity research
XWELL, Inc. XWEL
Services-Personal Services · SIC 7200 · Vertical: Services-Personal Services (SIC 7200)
XWELL is a wellness services company that until recently operated almost entirely in airports through the XpresSpa, XpresTest and Naples Wax Center brands. In July 2026 it announced the sale of its airport operations to focus on off-airport wellness businesses, a change that significantly reshapes the company.
At the close of 02 Nov 2026, XWELL, Inc. (XWEL) stock was 0.72 USD (+3.68% on the day), with market capitalisation 6.1 m USD, beta 0.47, 52-week range 0.29–1.70 USD. Latest reported quarter (Q2 2026): revenue of 7.1 m USD (−7.1% YoY), net income of -2.2 m USD, diluted EPS -0.26 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 42.5
- weak (30–45)
- Bollinger (20, 2)
- 0.61 – 0.89
- in the lower half of the band · %B 0.37 · band width 37.2%
- SMA 50 / 200
- 0.86 / 1.00
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.04 / -0.05
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −14.8% | −2.3% | −12.5 pp | — |
| 3 months | −34.4% | −0.8% | −33.6 pp | — |
| 6 months | −46.2% | +4.7% | −50.9 pp | — |
| Year to date | +55.5% | +10.2% | +45.4 pp | — |
| 1 year | −18.7% | +10.3% | −29.0 pp | −10.8% |
| 3 years | −55.8% | +73.0% | −128.9 pp | +15.0% |
| 5 years | −97.4% | +61.8% | −159.2 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.4 m | 7.5 m | 7.0 m | 7.7 m | 7.3 m | 7.2 m | 6.6 m | 7.1 m |
| Cost of revenue | 6.4 m | 6.3 m | 5.7 m | 5.9 m | 5.9 m | 4.2 m | 4.3 m | 4.2 m |
| Gross profit | 2.1 m | 1.1 m | 1.3 m | 1.8 m | 1.5 m | 2.9 m | 2.4 m | 2.9 m |
| SG&A | 6.4 m | 4.8 m | 4.3 m | 4.3 m | 1.6 m | 5.9 m | 7.6 m | 4.7 m |
| Operating income | -4.8 m | -7.7 m | -3.2 m | -2.7 m | -770.0 k | -9.1 m | -5.4 m | -2.1 m |
| Depreciation & amortisation | 252.0 k | 233.0 k | 166.0 k | 187.0 k | 221.0 k | 288.0 k | 172.0 k | 163.0 k |
| Interest expense | — | — | — | — | — | — | 53.0 k | 0 |
| Pre-tax income | -4.7 m | -7.6 m | -4.6 m | -2.0 m | -209.0 k | -9.3 m | -11.0 m | -1.8 m |
| Income tax | — | — | — | 34.0 k | 2.0 k | -7.0 k | — | 51.0 k |
| Net income | -4.8 m | -7.6 m | -4.7 m | -2.3 m | -724.0 k | -9.3 m | -11.2 m | -2.2 m |
| Diluted EPS | -0.99 | -1.44 ≈ | -1.00 | -0.56 | -0.26 | -1.60 ≈ | -1.51 | -0.26 |
| Operating cash flow | -3.4 m ≈ | -3.5 m | -4.2 m | -2.4 m ≈ | -2.1 m ≈ | -42.0 k | -4.6 m | -4.5 m ≈ |
| Capex | 410.0 k ≈ | 729.0 k | 424.0 k | 889.0 k ≈ | 945.0 k ≈ | 706.0 k | 390.0 k | 169.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.1 m | 48.5 m | 8.4 m | 73.7 m | 55.9 m | 30.1 m | 33.9 m | 29.2 m |
| Revenue YoY | +2.6% | −3.2% | −82.7% | +779.3% | −24.1% | −46.2% | +12.6% | −13.8% |
| Net income | -37.2 m | -21.2 m | -90.5 m | 3.3 m | -32.8 m | -27.7 m | -16.9 m | -17.0 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | −1,080.5% | unavailable | unavailable | unavailable |
| Diluted EPS | unavailable | unavailable | -2.05 | 0.03 | -7.01 | -6.64 | -3.66 | -5.08 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | −23,466.7% | unavailable | unavailable | unavailable |
| net % | -74.3% | -43.7% | -1,079.2% | 4.5% | -58.7% | -92.1% | -49.7% | -58.2% |
| Free cash flow | -9.6 m | -2.4 m | -29.0 m | 10.3 m | -30.7 m | -18.0 m | -12.8 m | -11.7 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 2.6 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- -12.8 m USD
- Total assets
- 11.2 m USD
- Debt / equity
- unavailable
- Current ratio
- 0.46x
- ROE
- unavailable
- ROA
- -92.9%
- FCF margin
- -40.0%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 8.4 m | 73.7 m | 55.9 m | 30.1 m | 33.9 m | 29.2 m | SEC (XBRL)· 01 Apr 2026verified |
| Cost of revenue | 12.0 m | 41.4 m | 43.9 m | 26.4 m | 25.0 m | 21.7 m | SEC (XBRL)· 01 Apr 2026verified |
| Gross profit | -3.6 m ≈ | 32.3 m | 12.0 m | 3.7 m | 8.9 m | 7.5 m | SEC (XBRL)· 01 Apr 2026verified |
| SG&A | 15.9 m | 24.2 m | 21.2 m | 13.0 m | 20.1 m | 16.0 m | SEC (XBRL)· 01 Apr 2026verified |
| Operating income | -40.1 m | 4.1 m | -31.2 m | -28.2 m | -16.7 m | -15.7 m | SEC (XBRL)· 01 Apr 2026verified |
| Depreciation & amortisation | 5.2 m | 3.2 m | 5.4 m | 2.1 m | 938.0 k | 862.0 k | SEC (XBRL)· 01 Apr 2026verified |
| EBITDA | -34.9 m ≈ | 7.3 m ≈ | -25.7 m ≈ | -26.1 m ≈ | -15.8 m ≈ | -14.8 m ≈ | SEC (XBRL)· 01 Apr 2026derived |
| Interest expense | — | — | — | — | — | 41.0 k | SEC (XBRL)· 01 Apr 2026verified |
| Pre-tax income | -92.2 m | 2.9 m | -32.6 m | -28.0 m | -16.4 m | -16.1 m | SEC (XBRL)· 01 Apr 2026verified |
| Income tax | 7.0 k | 56.0 k | 55.0 k | 35.0 k | 49.0 k | 29.0 k | SEC (XBRL)· 01 Apr 2026verified |
| Net income | -90.5 m | 3.3 m | -32.8 m | -27.7 m | -16.9 m | -17.0 m | SEC (XBRL)· 01 Apr 2026verified |
| Diluted EPS | -2.05 | 0.03 | -7.01 | -6.64 | -3.66 | -5.08 | SEC (XBRL)· 01 Apr 2026verified |
| Weighted average diluted shares | 44.6 m | 105.1 m | 4.7 m | 4.2 m | 4.6 m | 5.6 m | SEC (XBRL)· 01 Apr 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue; Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 89.8 m | 105.5 m | 19.0 m | 8.4 m | 4.6 m | 2.6 m | SEC (XBRL)· 01 Apr 2026verified |
| Receivables | — | 615.0 k | 2.9 m | 1.7 m | 1.8 m | 1.6 m | SEC (XBRL)· 01 Apr 2026verified |
| Inventories | 657.0 k | 1.8 m | 1.2 m | 900.0 k | 501.0 k | 509.0 k | SEC (XBRL)· 01 Apr 2026verified |
| Current assets | 91.8 m | 109.0 m | 47.3 m | 26.6 m | 15.3 m | 5.9 m | SEC (XBRL)· 01 Apr 2026verified |
| Property, plant & equipment, net | 4.2 m | 6.7 m | 3.7 m | 2.5 m | 1.8 m | 1.7 m | SEC (XBRL)· 01 Apr 2026verified |
| Goodwill | — | — | 4.0 m | 1.4 m | 1.4 m | — | SEC (XBRL)· 15 Apr 2025verified |
| Intangibles (excl. goodwill) | 870.0 k | 3.7 m | 4.0 m | 1.4 m | 1.0 m | 101.0 k | SEC (XBRL)· 01 Apr 2026verified |
| Total assets | 103.1 m | 127.3 m | 70.4 m | 39.0 m | 25.4 m | 11.2 m | SEC (XBRL)· 01 Apr 2026verified |
| Accounts payable | 2.4 m | 5.5 m | 2.3 m | 1.1 m | 1.6 m | 2.8 m | SEC (XBRL)· 01 Apr 2026verified |
| Long-term debt | 5.7 m | 3.6 m | — | — | — | — | SEC (XBRL)· 31 Mar 2022verified |
| Current liabilities | 13.5 m | 19.8 m | 11.0 m | 9.3 m | 9.2 m | 12.9 m | SEC (XBRL)· 01 Apr 2026verified |
| Total liabilities | 22.8 m | 27.3 m | 22.5 m | 18.0 m | 17.6 m | 23.8 m | SEC (XBRL)· 01 Apr 2026verified |
| Equity | 80.4 m | 99.9 m | 47.9 m | 21.0 m | 7.7 m | -12.8 m | SEC (XBRL)· 01 Apr 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -25.0 m | 14.6 m | -24.2 m | -16.1 m | -11.0 m | -8.7 m | SEC (XBRL)· 01 Apr 2026verified |
| Capex | 4.0 m | 4.3 m | 6.5 m | 1.9 m | 1.8 m | 3.0 m | SEC (XBRL)· 01 Apr 2026verified |
| Free cash flow | -29.0 m ≈ | 10.3 m ≈ | -30.7 m ≈ | -18.0 m ≈ | -12.8 m ≈ | -11.7 m ≈ | SEC (XBRL)· 01 Apr 2026derived |
| Investing cash flow | -4.3 m | -5.2 m | -34.8 m | 5.7 m | 5.9 m | 4.3 m | SEC (XBRL)· 01 Apr 2026verified |
| Financing cash flow | 117.2 m | 6.4 m | -27.4 m | 8.0 k | 1.4 m | 1.9 m | SEC (XBRL)· 01 Apr 2026verified |
| Share repurchases | — | 7.8 m | 23.8 m | — | — | — | SEC (XBRL)· 17 Apr 2023verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
02 Nov 2026Source: olivLaw, closing series
Market cap: 6.1 m USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -82.9% | 0 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -19.5% | 0 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -422.9x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 2.3x | 100 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -219.3% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial0/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
XWELL, Inc. (XWEL). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 29.2 m USD in 2025; YoY growth -13.8%; net margin -82.9%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 2.3x
What contradicts it
- Net margin: -82.9%
- Revenue CAGR 3Y: -19.5%
- Interest coverage: -422.9x
- FCF yield: -219.3%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Personal Services (SIC 7200) · same industry (4-digit SIC) · compared with 10 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| SCIService Corporation International | 10.6 bn | 19.3 | 35.7% | 12.7% | +2.9% | −2% / +27% |
| HRBH&R Block Inc | 6.4 bn | 9.2 | 710.9% | 18.6% | +4.9% | +24% / +15% |
| YELPYelp Inc | 1.1 bn | 9.5 | 18.2% | 8.6% | +3.7% | −31% / −55% |
| CSVCarriage Services, Inc. | 555.1 m | 12.5 | 17.3% | 10.7% | +3.3% | −19% / +55% |
| EVIEVI Industries, Inc. | 286.7 m | 46.0 | 5.3% | 1.7% | +14.6% | +8% / −15% |
| WWWw International, Inc. | 133.9 m | 0.1 | 332.6% | 148.1% | −11.6% | −53% / unavailable |
| RGSRegis Corporation | 73.7 m | 12.2 | 3.7% | 3.1% | +6.8% | +10% / +329% |
| DLPNDolphin Entertainment, Inc. | 12.4 m | — | -51.6% | -6.3% | +9.7% | −41% / −70% |
| XWELXWELL, Inc. | 6.1 m | — | — | -82.9% | −13.8% | −19% / −56% |
| UNFUnifirst Corporation | — | 42.9 | 5.0% | 4.3% | +3.7% | +50% / +50% |
| MRMMedirom Healthcare Technologies Inc. | — | — | 26.0% | 1.8% | +21.5% | −84% / −93% |
1- and 3-year price returns: for XWEL from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
XWELL is a wellness services company that until recently operated almost entirely in airports through the XpresSpa, XpresTest and Naples Wax Center brands. In July 2026 it announced the sale of its airport operations to focus on off-airport wellness businesses, a change that significantly reshapes the company 2.
SWOT
Strengths
- A presence in busy airports with steady traveler traffic and an operating model adaptable to small spaces 1.
- Recognition of the XpresSpa brand and a portfolio of brands that can be extended beyond airports 1.
- A long-standing partnership with the CDC for bio surveillance, a distinctive capability in the field 3.
Weaknesses
- The company has reported repeated net losses and needed additional capital to sustain its activities 1.
- Some Naples Wax Center locations faced operating difficulties, which led to recognized impairment charges 1.
- Internal control over financial reporting has been identified as having material weaknesses 1.
Opportunities
- Expansion outside airports through urban locations and med spa acquisitions could diversify revenue sources 1.
- If the sale of airport operations completes, the company could focus on its off-airport wellness businesses 2.
- International expansion of biosecurity programs could open new contracts for the company 3.
Threats
- Reduced government funding for surveillance programs could significantly affect XpresTest revenue 1.
- A decline in traveler numbers or time spent in airports could reduce demand for services 1.
- Shareholder dilution could increase if future financing is raised through share issuance or convertible instruments 1.
Risks
- Going concernhigh
The financial statements were prepared on a going concern basis, and the company must raise additional capital to sustain operations 1. If financing is not available on acceptable terms, activities could be scaled back 1.
- Dependence on government fundinghigh
The bio surveillance program is partly funded by government contracts that may be reduced through the annual budget process 1. Such a reduction would affect an important segment 1.
- Sale of airport operationsmedium
The sale depends on stockholder approval and closing conditions, and completion is not assured 2. If the transaction fails, the reorientation plan could be delayed 2.
- Shareholder dilutionmedium
Convertible instruments and warrants issued in 2025 and 2026 could dilute existing shareholders if exercised or converted 13. Price adjustment terms could amplify this effect 1.
- Internal control weaknesseslow
The company identified material weaknesses in internal control over financial reporting, which could affect the accuracy of its financial statements 1. Remediation requires time and resources 1.
Investment thesis
What would need to be true (bull case)
- If the strategy of expansion outside airports proves effective, the company could build a wellness platform with more access points and a more diverse customer base 1.
- Capital raised in February 2026 and reduced operating costs could support a stronger balance sheet if the cost trend holds 3.
- The long-standing CDC relationship and international expansion of biosecurity programs could generate new revenue in the future 3.
What would break the thesis
- The company has reported net losses over several consecutive years, and dependence on external capital remains high 13.
- Government program revenue is vulnerable to budget changes, and expansion outside airports depends on execution that is still uncertain 1.
- If the sale of airport operations does not complete, the company could be left with a portfolio that is hard to reorganize and under continuing financial pressure 2.
What to watch
- Completion of the airport operations sale and the stockholder voteQ4 2026
- Trend in XpresTest revenue and new government contracts2027
- Net loss and cash flows after the salenext 10-K
- Naples Wax Center results and progress of off-airport locationsQ1 2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
XWELL, Inc. is a global wellness organization delivering restorative and health-focused services to travelers through three reportable operating segments: XpresSpa, XpresTest and Naples Wax Center 1. Revenue for fiscal 2025 was approximately 29.2 million USD 3. The company ended the year with a net loss attributable to XWELL of approximately 17.0 million USD 3.
The stated strategy aims at expansion outside the airport through acquisitions in the med spa sector and new locations in metropolitan areas, along with optimizing the airport portfolio into a leaner and more profitable business 1. The company opened a wellness center at Penn Station in New York in the fourth quarter of 2025 3.
In July 2026, XWELL agreed to sell its ownership interests in the entities comprising substantially all of its airport operations for aggregate cash consideration of approximately 13.0 million USD, subject to customary adjustments and stockholder approval 2. After completion, operations would consist primarily of non-airport wellness activities, including Naples Wax Center 2.
Segments
XpresSpa
XpresSpa offers premium spa services, including massage, nail and skin care, as well as spa and travel products, in airports in the United States and abroad. As of June 30, 2026 there were 16 domestic locations and nine international locations in Dubai, Abu Dhabi, Amsterdam and Istanbul 2. XpresSpa revenue was approximately 18.6 million USD in 2025 3.
XpresTest
XpresTest conducts bio surveillance monitoring in collaboration with the CDC and Ginkgo Bioworks, a program partially funded by government contracts 1. XpresCheck revenue was approximately 8.3 million USD in 2025 3. A three-year contract with a total base value of 22.2 million USD was entered in February 2025 and later amended 12.
Market context
The airport retail market differs from traditional retail through a steady flow of travelers and the dwell time between security and boarding 1. The company operates in some of the largest and most trafficked US airports, while the rest of the domestic market is fragmented and made up largely of small private entities 1. Demand for wellness outside airports, including med spa services, is named as a growth direction 1.
The company's business depends on consumer spending by travelers, which is sensitive to inflation, interest rates and global economic uncertainty 1. Funding for bio surveillance programs depends on government budgets, an important external variable 1.
Trends
- Demand for wellness and traveltailwind
Consumer interest in travel, health and wellness is presented by the company as a growth factor for its services 1. If this demand is sustained, it could support expansion of the business outside airports 1.
- Time spent in airportsmixed
Increased security requirements have led travelers to spend more time in airports, supporting demand for services such as those of XpresSpa 1. A decline in passenger numbers or post-security time would directly affect operations 1.
- Government funding for surveillanceheadwind
Bio surveillance revenue depends on CDC contracts, which may be reduced or eliminated through the annual congressional appropriations process 1. If funding declines, business development could be delayed 1.
- Shift toward off-airport wellnesstailwind
The company is reorienting its strategy toward locations in transit hubs and urban centers, as well as acquisitions, which could reduce dependence on airport traffic 12. Execution of this transition remains uncertain 1.
Competitive position
The company notes that the largest domestic airport competitor operates far fewer locations than XWELL, and the rest of the market is fragmented 1. In off-airport segments, competition includes spa chains, waxing salons and med spa clinics, though the sources do not name them explicitly 1.
For bio surveillance, the company depends on partnerships with Ginkgo Bioworks and government agencies, and competitive positions in testing can change quickly 1. A new partner, PieQ, was announced in February 2026 to develop a biosecurity forecasting platform 3.
- Largest domestic airport competitor
Operates fewer locations than XWELL, as stated in the annual report 1.
- Fragmented private airport operators
The domestic airport market is made up largely of small private entities 1.
- Ginkgo Bioworks
Partner of XpresTest in the bio surveillance program, not a direct competitor 1.
- PieQ
New partner for a biosecurity forecasting platform, announced in 2026 3.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report29 Oct 2026Shareholder vote · Financial statements and exhibits
- Current report20 Oct 2026Delisting notice
- Proxy statement08 Oct 2026
- Current report08 Oct 2026Material agreement · Financial statements and exhibits
- Quarterly report14 Aug 2026
- Current report05 Aug 2026Departure or appointment of officers · Regulation FD disclosure · Financial statements and exhibits
- Current report09 Jul 2026Material agreement · Regulation FD disclosure · Financial statements and exhibits
- Quarterly report20 May 2026
- Current report (amendment)10 Apr 2026Shareholder vote
- Current report01 Apr 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / XWELL, Inc. · 01 Apr 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / XWELL, Inc. · 14 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / XWELL, Inc. · 01 Apr 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.